Advisory Committee Questions
2. If your answer to Question 1 is “yes,” are there sufficient data to support an OTC switch of loratadine for CIU or a more general urticaria claim.
If not, what other types of data are needed (such as clinical trial(s) for efficacy, safety label comprehension, or actual use)?